NEUROCRITIC PATIENTS
Conditions
Brief summary
Sedation variables: RASS scale, Bispectral Index (BIS), Delta BIS index, required doses of intravenous or inhalation sedation during the study period, Placement of the Sedaconda device: in the mouth or on the inspiratory branch, recording of the ISOef value (expiratory fraction gas) during the study period. The upper permitted ISOef limit will be set at 1%. Respiratory, hemodynamic variables, neuromomitorization and infectious status
Detailed description
Adverse effects observed throughout the study. • Awakening time and presence/absence of delirium in this patient awakening process. • Alteration of liver function throughout the study. • Alteration of kidney function throughout the study. • Days spent in ICU. • Days spent in the hospital. • Mortality in ICU. • Hospital mortality, Data based on analgesia will be collected: Values obtained with NOL (Annex 9). The value indicates the degree of nociception and the required doses of intravenous opioids during the study period.
Interventions
DRUGPROPOFOL
DRUGISOFLURANE
DRUGMIDAZOLAM
Sponsors
Hospital Universitari De Girona Doctor Josep Trueta
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sedation variables: RASS scale, Bispectral Index (BIS), Delta BIS index, required doses of intravenous or inhalation sedation during the study period, Placement of the Sedaconda device: in the mouth or on the inspiratory branch, recording of the ISOef value (expiratory fraction gas) during the study period. The upper permitted ISOef limit will be set at 1%. Respiratory, hemodynamic variables, neuromomitorization and infectious status | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse effects observed throughout the study. • Awakening time and presence/absence of delirium in this patient awakening process. • Alteration of liver function throughout the study. • Alteration of kidney function throughout the study. • Days spent in ICU. • Days spent in the hospital. • Mortality in ICU. • Hospital mortality, Data based on analgesia will be collected: Values obtained with NOL (Annex 9). The value indicates the degree of nociception and the required doses of intravenous opioids during the study period. | — |
Countries
Spain
Outcome results
None listed